|
|  |
|
in-cites,
August 2006
Citing URL: http://www.in-cites.com/institutions/JoslinDiabetesCenter.html
|
|
|
|
An
interview with:
Joslin Diabetes Center |
|
|
|
 arlier
this year, the Joslin Diabetes Center was named a Rising
Star in the field of Biology & Biochemistry. According
to Essential Science Indicators ,
Joslin’s current record in this field includes 177 papers
cited a total of 6,092 times to date. Their record also
includes 376 papers cited a total of 13,282 times to date in
the field of Clinical Medicine. This month, in-cites talks
with Dr. George King about Joslin’s citation achievements.
Dr. King is the Director of Research and Head of the Section
on Vascular Cell Biology at Joslin Diabetes Center, as well as
Professor of Medicine at Harvard Medical School.
|
How do you account for Joslin Diabetes Center’s significant
increase in the number of citations in the field of Biology &
Biochemistry in recent years?
The increase in citations is due to multiple factors:
- Our investigators are publishing a large number of papers on
subjects because they are on the cutting edge of biology and
biochemistry. Their findings have stimulated a great deal of
excitement for many investigators not only in the areas of
diabetes and obesity, but also in
 the general basic sciences—immunology,
cell signaling, vascular cell biology, and genetics.
- Joslin has recruited several important scientists in the areas
of immunology, stem cell biology, and developmental biology.
These investigators have published a number of exciting new
papers, thereby increasing the visibility of Joslin Diabetes
Center.
- Diabetes, its complications, and obesity are among the hottest
research topics in the field, both in clinical and basic
science. Therefore, a large number of investigators have
ventured into these areas, which have long been an interest of
Joslin scientists. Because the number of papers published in
these areas has greatly increased, this could partially explain
the increase in citations.
Does this reflect a deliberate plan to enhance the
Center’s research effort in this field, or was this an unexpected or
serendipitous development?
Our strategic plans have been formulated over the last five to
seven years with extension into multiple fields. Clearly this is
part of our strategic plan and therefore is not a serendipitous
development.
Are there specific areas of research within the realm of
diabetes on which the center particularly focuses?
|
“Since 1898, Joslin Diabetes Center has focused its efforts on understanding and finding treatments for people with diabetes.”
|
|
Photo by MJMaloney 2005 |
|
Joslin Diabetes Center has a narrow mission—to conquer diabetes
in all
of its forms—but a wide research base. Our main focus is on
diabetes, obesity, and associated complications, both in clinical
and basic research. However, within those areas we have broad
interests, including: immunology, stem cell biology, cell signaling,
adipocyte biology, genetics, epidemiology, vascular cell biology,
hypertension, diabetic retinopathy, mental health, and many other
topics related to diabetes.
What factors or circumstances led the Center to its work
in this field?
Since 1898, Joslin Diabetes Center has focused its efforts on
understanding and finding treatments for people with diabetes. Thus
we have a longstanding interest in this area. Over the last 20 years
we have focused our efforts mainly in basic and clinical research to
understand the causes of type 1 diabetes, type 2 diabetes, and
vascular complications. Our recent effort has been to translate the
basic information into new therapies for the prevention and
treatment of type 1 and type 2 diabetes and their frequent
complications.
What is your prediction for the state of our knowledge
about this particular field 10 years from now?
The basic science on the causes of type 1 and type 2 diabetes and
its complications is rapidly advancing. There is a great deal of
interest and many findings in clinical and
translational research.
Therefore, I believe that over the next 10 years there will be
tremendous advances in the understanding of the causes of diabetes.
In addition, translational research will produce important
information and new therapies for the prevention and treatment of
type 1 and type 2 diabetes and its complications.
What research fields or capabilities do you see as
critical for the future of the Center?
In the next few years, the areas of strategic importance will be
clinical research with regard to type 1 and type 2 diabetes, stem
cell biology, transplantation immunology, prevention of type 1
diabetes, vascular biology, neuroscience, and cardiovascular
disease.
What are the implications of the Center’s work for the
future of this particular field or neighboring fields?
The scientific areas being explored in Joslin Diabetes Center’s
Research Division have important implications for all sciences.
Examples include the understanding of T-cell action, regulation of
energy metabolism, and basic signaling of cytokines. Our
translational research on imaging of the retina and the pancreas
will also be critical models for the study of other diseases.
George L. King, MD, Director of Research and Head of the Section
on Vascular Cell Biology
Joslin Diabetes Center
Boston, MA, USA
| Joslin Diabetes Center's
most-cited paper with 462 cites to date: |
|
Shepherd PR, Withers DJ, Siddle K, "Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling,"
Biochem. J. 333:471-90, 1 August 1998. |
|
Source:
Essential Science Indicators |
|
|
|
|
in-cites, August 2006
Citing URL: http://www.in-cites.com/institutions/JoslinDiabetesCenter.html
|
|
cites
